[en] Invasive pulmonary aspergillosis (IPA) is an increasingly recognised problem in critically ill patients. Little is known about how intensivists react to an Aspergillus-positive respiratory sample or the efficacy of antifungal therapy (AFT). This study aimed to identify drivers of AFT prescription and diagnostic workup in patients with Aspergillus isolation in respiratory specimens as well as the impact of AFT in these patients. ICU patients with an Aspergillus-positive respiratory sample from the database of a previous observational, multicentre study were analysed. Cases were classified as proven/putative IPA or Aspergillus colonisation. Demographic, microbiological, diagnostic and therapeutic data were collected. Outcome was recorded 12 weeks after Aspergillus isolation. Patients with putative/proven IPA were more likely to receive AFT than colonised patients (78.7% vs. 25.5%; P <0.001). Patients with host factors for invasive fungal disease were more likely to receive AFT (72.5% vs. 37.4%) as were those with multiorgan failure (SOFA score >7) (68.4% vs. 36.9%) (both P <0.001). Once adjusted for disease severity, initiation of AFT did not alter the odds of survival (HR = 1.40, 95% CI 0.89-2.21). Likewise, treatment within 48 h following diagnosis did not change the clinical outcome (75.7% vs. 61.4%; P = 0.63). Treatment decisions appear to be based on diagnostic criteria and underlying disease severity at the time of Aspergillus isolation. IPA in this population has a dire prognosis and AFT is not associated with reduced mortality. This may be explained by delayed diagnosis and an often inevitable death due to advanced multiorgan failure.
Kosmidis, C., Denning, D., The clinical spectrum of pulmonary aspergillosis. Thorax 70 (2015), 270–277.
De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46 (2008), 1813–1821.
Meersseman, W., Vandecasteele, S.J., Wilmer, A., Verbeken, E., Peetermans, W.E., Van Wijngaerden, E., Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170 (2004), 621–625.
Garnacho-Montero, J., Amaya-Villar, R., Ortiz-Leyba, C., León, C., Alvarez-Lerma, F., Nolla-Salas, J., et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 9 (2005), R191–9.
Vandewoude, K.H., Blot, S., Benoit, D., Depuydt, P., Vogelaers, D., Colardyn, F., Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 59 (2004), 251–257.
Taccone, F.S., Van den Abeele, A.M., Bulpa, P., Misset, B., Meersseman, W., Cardoso, T., et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions and outcomes. Crit Care, 19, 2015, 7.
Lugosi, M., Alberti, C., Zahar, J.R., Garrouste, M., Lemiale, V., Descorps-Desclère, A., et al. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect 69 (2014), 284–292.
Vandewoude, K.H., Blot, S.I., Depuydt, P., Benoit, D., Temmerman, W., Colardyn, F., et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care, 10, 2006, R31.
Bansal, A., Pande, A., Newer antifungal agents: scope of clinical misuse in intensive care units. J Patient Safety Infect Control 1 (2013), 25–26.
Blot, S., Janssens, R., Claeys, G., Hoste, E., Buyle, F., De Waele, J.J., et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 58 (2006), 474–477.
Alanio, A., Cabaret, O., Sitterlé, E., Costa, J.M., Brisse, S., Cordonnier, C., et al. Azole preexposure affects the Aspergillus fumigatus populations in patients. Antimicrob Agents Chemother 56 (2012), 4948–4950.
Fournier, P., Schwebel, C., Maubon, D., Vesin, A., Lebeau, B., Foroni, L., et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J Antimicrob Chemother 66 (2011), 2880–2886.
Blot, S.I., Taccone, F.S., Van den Abeele, A.M., Bulpa, P., Meersseman, W., Brusselaers, N., et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 186 (2012), 56–64 Erratum in: Am J Respir Crit Care Med 2012;186:808.
Koulenti, D., Garnacho-Montero, J., Blot, S., Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis 27 (2014), 174–183.
Nivoix, Y., Velten, M., Letscher-Bru, V., Moghaddam, A., Natarajan-Amé, S., Fohrer, C., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47 (2008), 1176–1184.
Greene, R.E., Schlamm, H.T., Oestmann, J.W., Stark, P., Durand, C., Lortholary, O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44 (2007), 373–379.
Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 43 (2006), 577–584.
Marchiori, E., Zanetti, G., Escuissato, D.L., Souza, A.S. Jr, de Souza Portes Meirelles, G., Fagundes, J., et al. Reversed halo sign: high-resolution CT scan findings in 79 patients. Chest 141 (2012), 1260–1266.
Marchiori, E., Marom, E.M., Zanetti, G., Hochhegger, B., Irion, K.L., Godoy, M.C.B., Reverse halo sign in invasive fungal infections: criteria for differentiation from organizing pneumonia. Chest 142 (2012), 1469–1473.
Stanzani, M., Battista, G., Sassi, C., Lewis, R.E., Tolomelli, G., Clissa, C., et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 54 (2012), 610–615.
Maertens, J., Maertens, V., Theunissen, K., Meersseman, W., Meersseman, P., Meers, S., et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 49 (2009), 1688–1693.
Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005), 1242–1250.
Meersseman, W., Lagrou, K., Maertens, J., Wilmer, A., Hermans, G., Vanderschueren, S., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177 (2008), 27–34.
Acosta, J., Catalan, M., del Palacio-Peréz-Medel, A., Lora, D., Montejo, J.C., Cuetara, M.S., et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→3)-β-D-glucan chromogenic assay in serum samples. Clin Microbiol Infect 17 (2011), 1053–1060.
Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002), 408–415.
Burghi, G., Lemiale, V., Seguin, A., Lambert, J., Lacroix, C., Canet, E., et al. Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 37 (2011), 1605–1612.
Mayer, J., Doubek, M., Vorlicek, J., Must we really fear toxicity of conventional amphotericin B in oncological patients?. Support Care Cancer 7 (1999), 51–55.
Nath, C.E., Shaw, P.J., Gunning, R., McLachlan, A.J., Earl, J.W., Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 43 (1999), 1417–1423.
Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004), 1563–1571.
Batista, M.V., Costa, S.F., Shikanai-Yasuda, M.A., Moss, R.B., Current treatment options for invasive aspergillosis. Drugs Today (Barc) 49 (2013), 213–226.
Madureira, A., Bergeron, A., Lacroix, C., Robin, M., Rocha, V., de Latour, R.P., et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 30 (2007), 551–554.
Garnacho-Montero, J., Olaechea, P., Alvarez-Lerma, F., Alvarez-Rocha, L., Blanquer, J., Galván, B., et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter 26 (2013), 173–188.
Marr, K.A., Schlamm, H., Herbrecht, R., Rottinghaus, S.T., Bow, E.J., Cornely, O.A., et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162 (2015), 81–89.
Cornely, O.A., Maertens, J., Bresnik, M., Ebrahimi, R., Dellow, E., Herbrecht, R., et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 54 (2011), 449–455.
Blot, S., Pea, F., Lipman, J., The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77 (2014), 3–11.
